 NEW YORK, July 14, 2021 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract has been accepted at the Alzheimers Association International Conference AAIC, which will be held online and in-person July 26-30, 2021. The Companys lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimers Disease AD Patients: A Regenerative Therapeutic Strategy. 